المؤلفون: N.I. Weijl, Carin A. Uyl-de Groot, Lidwine W. Tick, Andre M. Bergman, Winald R. Gerritsen, Daan ten Bokkel Huinink, Hans M. Westgeest, Jules Lavalaye, Katja K.H. Aben, Inge M. van Oort, Fons A.J.M. van den Eertwegh, Malou C.P. Kuppen, Menuhin I. Lampe, Yes A J van de Wouw, Jeroen R.J.A. van Moorselaar, Joan van den Bosch, Juleon L.L.M. Coenen, Rik D.M. Somford, Tineke J. Smilde, Niven Mehra, Mathijs P. Hendriks

المساهمون: Internal medicine, CCA - Cancer biology and immunology, Urology, CCA - Cancer Treatment and quality of life, Health Technology Assessment (HTA)

المصدر: Westgeest, H M, Kuppen, M C P, van den Eertwegh, F A J M, van Oort, I M, Coenen, J L L M, van Moorselaar, J R J A, Aben, K K H, Bergman, A M, Huinink, D T B, van den Bosch, J, Hendriks, M P, Lampe, M I, Lavalaye, J, Mehra, N, Smilde, T J, Somford, R D M, Tick, L, Weijl, N I, van de Wouw, Y A J, Gerritsen, W R & Groot, C A U 2021, ' High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients : Results from the Dutch CAPRI-Registry ', Journal of Palliative Medicine, vol. 24, no. 12, pp. 1789-1797 . https://doi.org/10.1089/jpm.2020.0800
Journal of Palliative Medicine, 24(12), 1789-1797. Mary Ann Liebert Inc.
Journal of Palliative Medicine, 24, 12, pp. 1789-1797
Journal of Palliative Medicine, 24, 1789-1797

مصطلحات موضوعية: Male, medicine.medical_specialty, Medical Overuse, Castration resistant, Prostate cancer, SDG 3 - Good Health and Well-being, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Humans, Medicine, Registries, General Nursing, Netherlands, Retrospective Studies, Terminal Care, business.industry, High intensity, General Medicine, medicine.disease, Prostatic Neoplasms, Castration-Resistant, Anesthesiology and Pain Medicine, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Emergency medicine, Hospital admission, business, End-of-life care, Life phase

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df4add06b482c8b42c6f4158cc5bdf89
https://research.vumc.nl/en/publications/13bcb35e-f6d1-4c15-a1e8-8d67db323f51

المؤلفون: Haiko J. Bloemendal, Niven Mehra, Marco B. Polee, Joan van den Bosch, Alphonsus J. M. van den Eertwegh, Carin A. Uyl-de Groot, Daan ten Bokkel Huinink, H. P. (Pieter) van den Berg, Andre M. Bergman, Inge M. van Oort, Malou C.P. Kuppen, Addy C. M. van de Luijtgaarden, Laurent M.C.L. Fossion, Mathijs P. Hendriks, Juleon L.L.M. Coenen, Winald R. Gerritsen, Hans M. Westgeest, A.C.M. van den Bergh, Ronald de Wit, N.I. Weijl

المساهمون: Health Technology Assessment (HTA), Medical Oncology, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Medical oncology, CCA - Cancer Treatment and quality of life

المصدر: Clinical Genitourinary Cancer, 17, 5, pp. e946-e956
Clinical Genitourinary Cancer, 17(5), E946-E956. Elsevier
Clinical genitourinary cancer, 17(5), E946-E956. CIG MEDIA GROUP, LP
Westgeest, H M, Kuppen, M C P, van den Eertwegh, A J M, de Wit, R, Coenen, J L L M, van den Berg, H P, Mehra, N, van Oort, I M, Fossion, L M C L, Hendriks, M P, Bloemendal, H J, van de Luijtgaarden, A C M, ten Bokkel Huinink, D, van den Bergh, A C M, van den Bosch, J, Polee, M B, Weijl, N, Bergman, A M, Uyl-de Groot, C A & Gerritsen, W R 2019, ' Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands ', Clinical Genitourinary Cancer, vol. 17, no. 5, pp. e946-e956 . https://doi.org/10.1016/j.clgc.2019.05.018
Clinical Genitourinary Cancer, 17(5), e946-e956. Elsevier
Clinical Genitourinary Cancer, 17, e946-e956

مصطلحات موضوعية: Male, Oncology, medicine.medical_treatment, 030232 urology & nephrology, PLUS PREDNISONE, Androgen deprivation therapy, Prostate cancer, chemistry.chemical_compound, 0302 clinical medicine, Medicine, Neoplasm Metastasis, Netherlands, DOCETAXEL, Clinical Trials as Topic, education.field_of_study, CYCLES, Abiraterone acetate, Standard of Care, MEN, Middle Aged, CHEMOTHERAPY, Prognosis, OPEN-LABEL, ABIRATERONE ACETATE, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, Docetaxel, Cabazitaxel, SAFETY, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], 030220 oncology & carcinogenesis, POSTDOCETAXEL, Taxoids, medicine.drug, Registry, medicine.medical_specialty, Urology, Population, INCREASED SURVIVAL, Antineoplastic Agents, 03 medical and health sciences, Trial eligibility, SDG 3 - Good Health and Well-being, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Humans, Real-world outcomes, education, Aged, Retrospective Studies, Chemotherapy, L-Lactate Dehydrogenase, business.industry, Prostate-Specific Antigen, medicine.disease, Survival Analysis, Trial population, Clinical trial, chemistry, business

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c55db3d2d7c2abd92a4b76a9b4278c5e
https://doi.org/10.1016/j.clgc.2019.05.018

المؤلفون: Diederik M. Somford, Reindert J.A. van Moorselaar, Carin A. Uyl-de Groot, Ronald de Wit, Laurent M.C.L. Fossion, Niven Mehra, Hans M. Westgeest, Addy C. M. van de Luijtgaarden, Juleon L.L.M. Coenen, N.I. Weijl, Maud M. Geenen, Winald R. Gerritsen, Agnes J. van de Wouw, A.C.M. van den Bergh, Mathijs P. Hendriks, Marco B. Polee, Alphonsus J. M. van den Eertwegh, Andre M. Bergman, Malou C.P. Kuppen, Inge M. van Oort, Daan ten Bokkel Huinink

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Health Technology Assessment (HTA), Medical oncology, Urology, CCA - Cancer Treatment and quality of life, Internal medicine

المصدر: European urology oncology, 4(4), 618-627. De Tijdstroom/Elsevier
European Urology Oncology, 4, 618-627
European urology oncology, 4, 618-627. Elsevier
Kuppen, M C P, Westgeest, H M, van den Eertwegh, A J M, van Moorselaar, R J A, van Oort, I M, Coenen, J L L M, van den Bergh, A C M F, Mehra, N, Somford, D M, Bergman, A M, Ten Bokkel Huinink, D, Fossion, L, Geenen, M M, Hendriks, M P, van de Luijtgaarden, A C M, Polee, M B, Weijl, N I, van de Wouw, A J, de Wit, R, Uyl-de Groot, C A & Gerritsen, W R 2021, ' Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer : Results from the Dutch Castration-resistant Prostate Cancer Registry ', European Urology Oncology, vol. 4, no. 4, pp. 618-627 . https://doi.org/10.1016/j.euo.2019.09.005
European Urology Oncology, 4, 4, pp. 618-627
European Urology Oncology, 4(4), 618-627. Elsevier BV

مصطلحات موضوعية: Oncology, Male, ANTITUMOR-ACTIVITY, 030232 urology & nephrology, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, Prednisone, Medicine, Sequencing, Registries, Castration-resistant prostate cancer, DOCETAXEL, Abiraterone acetate, TIME, Prostatic Neoplasms, Castration-Resistant, TRIALS, Docetaxel, Pharmaceutical Preparations, Cabazitaxel, 030220 oncology & carcinogenesis, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Androgens, Cross resistance, medicine.drug, medicine.medical_specialty, CLINICAL-OUTCOMES, ENZALUTAMIDE, Urology, INCREASED SURVIVAL, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Antigen, SDG 3 - Good Health and Well-being, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Enzalutamide, Humans, Radiology, Nuclear Medicine and imaging, Real-world outcomes, Retrospective Studies, Androgen-receptor targeting agents, business.industry, Androgen Antagonists, medicine.disease, Androgen receptor, chemistry, Surgery, business

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5688ade1d20f2f2f131d73a057ff810
https://research.rug.nl/en/publications/41b16b5e-d8f6-46e7-904f-77d48f068028

المؤلفون: Carolien H. Smorenburg, Juleon L.L.M. Coenen, Alfons J.M. van den Eertwegh, Aart Beeker, H. Pieter van den Berg, Winald R. Gerritsen, Walter L. Vervenne, Henk M.W. Verheul, Linda de Munck, Esther W. Bouman-Wammes

المساهمون: Internal medicine, CCA - Cancer Treatment and quality of life, Medical oncology, CCA - Cancer Treatment and Quality of Life

المصدر: European Journal of Cancer, 90, pp. 1-9
Bouman-Wammes, E W, van den Berg, H P, de Munck, L, Beeker, A, Smorenburg, C H, Vervenne, W L, Coenen, J L L M, Verheul, H M W, Gerritsen, W R & van den Eertwegh, A J M 2018, ' A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial ', European Journal of Cancer, vol. 90, pp. 1-9 . https://doi.org/10.1016/j.ejca.2017.11.021
European Journal of Cancer, 90, 1-9
European Journal of Cancer, 90, 1-9. Pergamon
European journal of cancer (Oxford, England, 90, 1-9. Elsevier Limited

مصطلحات موضوعية: Oncology, Male, Cancer Research, medicine.medical_specialty, Combination therapy, medicine.medical_treatment, Docetaxel, Kaplan-Meier Estimate, Adenocarcinoma, urologic and male genital diseases, Disease-Free Survival, Carboplatin, 03 medical and health sciences, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, All institutes and research themes of the Radboud University Medical Center, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, 030212 general & internal medicine, neoplasms, Aged, Aged, 80 and over, Chemotherapy, business.industry, organic chemicals, Incidence (epidemiology), Middle Aged, medicine.disease, Interim analysis, Prostatic Neoplasms, Castration-Resistant, chemistry, 030220 oncology & carcinogenesis, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Early Termination of Clinical Trials, Taxoids, Neoplasm Recurrence, Local, business, therapeutics, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46627d79ce31233731263293df40e564
https://hdl.handle.net/2066/183699

المؤلفون: Juleon L.L.M. Coenen, Olaf Loosveld, Marco B. Polee, E. D. van Werkhoven, Geert Jan Creemers, Winald R. Gerritsen, A.J. ten Tije, Hielke J. Meulenbeld, Otilia Dalesio, P. C. De Jong, R. de Wit, Sophie D. Fossa

المساهمون: Medical Oncology, Medical oncology, CCA - Innovative therapy

المصدر: Meulenbeld, H J, van Werkhoven, E D, Coenen, J L L M, Creemers, G J, Loosveld, O J L, de Jong, P C, ten Tije, A J, Fossa, S D, Polee, M, Gerritsen, W R, Dalesio, O & de Wit, R 2012, ' Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro) ', European Journal of Cancer, vol. 48, no. 16, pp. 2993-3000 . https://doi.org/10.1016/j.ejca.2012.05.014
European Journal of Cancer, 48(16), 2993-3000. Elsevier Ltd.
European Journal of Cancer, 48, 2993-3000
European Journal of Cancer, 48, 16, pp. 2993-3000
European Journal of Cancer, 48(16), 2993-3000. Pergamon

مصطلحات موضوعية: Male, Oncology, Cancer Research, Time Factors, medicine.medical_treatment, Castration Resistant Prostate Cancer, Kaplan-Meier Estimate, Docetaxel, Prostate cancer, Immune Regulation [NCMLS 2], Risk Factors, Prostate, Prednisone, Antineoplastic Combined Chemotherapy Protocols, Netherlands, Aged, 80 and over, Bone Density Conservation Agents, Norway, Bone metastasis, Etidronic Acid, Bisphosphonates, Middle Aged, Treatment Outcome, medicine.anatomical_structure, Risedronic acid, Disease Progression, Taxoids, Risedronic Acid, medicine.drug, medicine.medical_specialty, Pain, Bone Neoplasms, Risk Assessment, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Humans, Castration, Aged, Proportional Hazards Models, Chemotherapy, Risedronate, business.industry, Bone metastases, Prostatic Neoplasms, Androgen Antagonists, Prostate-Specific Antigen, Bisphosphonate, medicine.disease, Antineoplastic Agents, Phytogenic, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbd244008e841890da76b8d8d1f03c6d
https://doi.org/10.1016/j.ejca.2012.05.014

المؤلفون: Winald R. Gerritsen, Juleon L.L.M. Coenen, P. C. De Jong, Geert Jan Creemers, R. de Wit, E. D. van Werkhoven, Marco B. Polee, Hielke J. Meulenbeld, Olaf Loosveld, A.J. ten Tije, Sophie D. Fossa, Otilia Dalesio

المصدر: Journal of Clinical Oncology. 29:4518-4518

مصطلحات موضوعية: Oncology, Cancer Research, Chemotherapy, medicine.medical_specialty, business.industry, medicine.medical_treatment, Bone metastasis, Pharmacology, Bisphosphonate, urologic and male genital diseases, medicine.disease, Prostate cancer, medicine.anatomical_structure, Docetaxel, Prostate, Prednisone, Internal medicine, medicine, Clinical endpoint, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::f74d94e3947570ff1ed73bd7fd196a3f
https://doi.org/10.1200/jco.2011.29.15_suppl.4518